An open-label investigator sponsored trial to investigate the safety, tolerability and development of subfoveal fibrosis by intravitreal administration of altering regimens of Fovista (Anti-PDGF-B pegylated aptamer) and Anti-VEGF therapy (Lucentis, Avastin or Eylea in subjects with neovascular age-related macular degeneration.

Trial Profile

An open-label investigator sponsored trial to investigate the safety, tolerability and development of subfoveal fibrosis by intravitreal administration of altering regimens of Fovista (Anti-PDGF-B pegylated aptamer) and Anti-VEGF therapy (Lucentis, Avastin or Eylea in subjects with neovascular age-related macular degeneration.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2015

At a glance

  • Drugs Pegpleranib (Primary) ; Aflibercept; Bevacizumab; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Feb 2015 Initial results were presented at the 12th Annual Bascom-Palmer Eye Institute Angiogenesis, Exudation, and Degeneration Meeting, according to an OphthoTech Corporation media release.
    • 24 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top